Next-Generation Obesity Drugs

✓ Medically reviewed | Published: | Evidence level: 1A
Eli Lilly's obesity portfolio spans injectable tirzepatide, the oral GLP-1 agonist orforglipron and the triple agonist retatrutide. Published trials show large average weight reductions, with differences in mechanism and convenience. Gastrointestinal side effects remain the most common tolerability issue across the class.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pharmacology

Quick Facts

Tirzepatide mechanism
GIP and GLP-1 agonist
Retatrutide mechanism
GIP, GLP-1, glucagon agonist
Orforglipron format
Oral, once daily

How do Lilly's obesity drugs differ in how they work?

Quick answer: Tirzepatide activates GIP and GLP-1 receptors, retatrutide adds glucagon receptor activity, and orforglipron is an oral small-molecule GLP-1 agonist.

Tirzepatide, a once-weekly injection, combines GIP and GLP-1 receptor agonism. In SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), the highest dose produced average weight loss of roughly 20% over 72 weeks in adults with obesity without diabetes. Retatrutide adds glucagon receptor activation, which may increase energy expenditure. A phase 2 trial (Jastreboff et al., NEJM, 2023) reported average reductions of about 24% at 48 weeks at the highest dose.

Orforglipron differs in format. It is a non-peptide molecule taken as a pill, which could simplify manufacturing and avoid cold-chain storage. Its phase 3 results, announced by Lilly, showed meaningful weight loss, generally somewhat less than injectable tirzepatide. A pill could widen access for people reluctant to use injections.

What are the safety questions and limits of these trial results?

Quick answer: Nausea, vomiting, diarrhea and constipation are most common, and weight regain after stopping and long-term outcome data remain open questions.

Gastrointestinal effects occur most often during dose escalation and are usually mild to moderate. Rarer concerns include gallbladder disease and pancreatitis, and clinicians monitor for them. Retatrutide's glucagon activity has prompted attention to heart rate and liver effects, which phase 3 trials are examining.

Trial averages hide wide individual variation, and participants in trials receive lifestyle counseling that may exceed real-world support. Weight tends to return after discontinuation, so long-term use is often needed. Cost, insurance coverage and supply will shape who can access these drugs. Patients should discuss candidacy, other conditions and pregnancy plans with a clinician.

Frequently Asked Questions

No head-to-head comparison should be assumed. Reported phase 3 results for the pill showed substantial weight loss, but injectable tirzepatide has generally shown larger average reductions.

Retatrutide has been in late-stage trials and was investigational at last report. Check current regulatory status with a clinician or the FDA.

No. Tirzepatide is approved for chronic weight management in adults with obesity, or overweight with a related condition, whether or not they have diabetes.

References

  1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
  2. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023.
  3. Reuters. Lilly says its obesity drugs helped patients lose weight in clinical trials. 2026.